Payment overview · 2025
General Payments
$1,151.29
54 reported records · 18 companies
Healthcare provider profile · identity verified
Garth B Tanner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MODESTO, CA · NPI 1184612624
Verified facts
What the public records show
CMS Open Payments records show Garth B Tanner, MD received $1,151.29 in general payments during 2025 across 54 reported records.
Amgen Inc. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $174.53 | 15.2% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $136.93 | 11.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $113.10 | 9.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $99.49 | 8.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $85.85 | 7.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.55 | 7.1% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $77.14 | 6.7% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $59.37 | 5.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.47 | 4.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.16 | 4.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.00 | 4.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.32 | 3.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.06 | 3.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $26.32 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.98 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.53 | 1.8% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $18.85 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.64 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,151.29 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $143.87 | 6 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $143.87 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $136.93 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $99.49 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $93.23 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $83.09 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $77.14 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.09 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.09 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $59.37 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $56.10 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.16 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $26.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 975 | 279 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 704 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 601 | 156 |
| Lisinopril | Lisinopril | 589 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 531 | 136 |
| Alprazolam | Alprazolam | 451 | 77 |
| Losartan Potassium | Losartan Potassium | 379 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 352 | 100 |
| Omeprazole | Omeprazole | 322 | 105 |
| Gabapentin | Gabapentin | 296 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 294 | 89 |
| Furosemide | Furosemide | 263 | 75 |
| Metformin Hcl | Metformin Hcl | 251 | 81 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 250 | 37 |
| Potassium Chloride | Potassium Chloride | 224 | 62 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 205 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 58 |
| Eliquis | Apixaban | 184 | 43 |
| Carvedilol | Carvedilol | 176 | 45 |
| Ozempic | Semaglutide | 167 | 35 |
| Simvastatin | Simvastatin | 157 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 149 | 29 |
| Trazodone Hcl | Trazodone Hcl | 144 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 137 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 49 |
| Montelukast Sodium | Montelukast Sodium | 121 | 36 |
| Estradiol | Estradiol | 120 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 36 |
| Jardiance | Empagliflozin | 118 | 31 |
| Metformin Hcl Er | Metformin Hcl | 118 | 32 |
| Tramadol Hcl | Tramadol Hcl | 115 | 28 |
| Famotidine | Famotidine | 106 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 35 |
| Finasteride | Finasteride | 103 | 29 |
| Ibuprofen | Ibuprofen | 103 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 23 |
| Sertraline Hcl | Sertraline Hcl | 97 | 23 |
| Ezetimibe | Ezetimibe | 91 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 39 |
| Glipizide Er | Glipizide | 90 | 27 |
| Allopurinol | Allopurinol | 80 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 61 |
| Atenolol | Atenolol | 76 | 20 |
| Glipizide | Glipizide | 76 | 24 |
| Celecoxib | Celecoxib | 74 | 16 |
| Clonazepam | Clonazepam | 71 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | suppressed |
| Gemtesa | Vibegron | 69 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 37 |
| Lovastatin | Lovastatin | 61 | 19 |
| Benazepril Hcl | Benazepril Hcl | 60 | 19 |
| Myrbetriq | Mirabegron | 60 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 56 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 56 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 18 |
| Synthroid | Levothyroxine Sodium | 54 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Baclofen | Baclofen | 49 | 18 |
| Clotrimazole | Clotrimazole | 49 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 43 |
| Labetalol Hcl | Labetalol Hcl | 48 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 11 |
| Rybelsus | Semaglutide | 46 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 22 |
| Alendronate Sodium | Alendronate Sodium | 44 | 12 |
| Meloxicam | Meloxicam | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Spironolactone | Spironolactone | 43 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 34 |
| Glimepiride | Glimepiride | 42 | 12 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | 15 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Premarin | Estrogens, Conjugated | 37 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | 18 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 12 |
| Dilt-Xr | Diltiazem Hcl | 32 | suppressed |
| Methadone Hcl | Methadone Hcl | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 27 | 12 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Prednisone | Prednisone | 24 | 13 |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Armodafinil | Armodafinil | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Naproxen | Naproxen | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Telmisartan | Telmisartan | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Fluocinolone Acetonide | Fluocinolone/Shower Cap | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Pentasa | Mesalamine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,151.29 · 54 records | Amgen Inc. | AIRSUPRA, AUSTEDO XR, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, Korlym, LEQVIO, Leqembi, MOUNJARO, OFEV, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error